In The News - Volume 2 - Issue 9 - February 28, 2016

TransMedics Announces The World's First Human Liver Transplantation Using The Organ Care System (OCS™) Liver Technology & The Initiation of The OCS™ Liver PROTECT U.S. Pivotal Trial
The transplant procedure was performed by Dr. James F. Markmann, Chief of Transplant Surgery at Massachusetts General Hospital.  Dr. Markmann is a principal investigator and Chairman of the Steering Committee for the PROTECT Trial.  "It is our hope that the ability to preserve a liver in the manner offered by the OCS technology will save lives by making the livers we use function better and by making more organs available for transplantation," said Dr. Markmann.
The OCS™ Liver PROTECT Trial is the first multi-center, randomized clinical trial in the United States for warm liver perfusion for transplantation.  It is designed to assess the impact of warm oxygenated perfusion of standard and expanded-criteria donor livers on post-transplant clinical outcomes as compared to cold storage.  The trial will be conducted at a network of up to 20 major liver transplant centers in the U.S.
Feb 23/16
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=154194#.VtOzwbn2aM8

Cleveland Clinic performs first U.S. uterus transplant
CLEVELAND -- Surgeons in Cleveland say they have performed the nation's first uterus transplant, a new frontier that aims to give women who lack wombs a chance at pregnancy.
In a statement Thursday, the Cleveland Clinic said the nine-hour surgery was performed a day earlier on a 26-year-old woman, using a uterus from a deceased donor.
The hospital had long been planning for such a surgery, announcing last fall a clinical trial that would attempt 10 transplants in women with what's called uterine factor infertility (UFI), meaning they were born without a uterus or with uterine abnormalities that block pregnancy.
Feb 25/16
http://www.cbsnews.com/news/cleveland-clinic-performs-first-us-uterus-transplant/

Urological complications following kidney transplantation in pediatric age: A single-center experience
Surgical complications during kidney transplantation can seriously affect renal outcomes. We assess occurrence, risk factors, and results of all urological complications in a series of renal transplants in a single center.
Children who underwent renal transplant between January 2008 and December 2014 were retrospectively evaluated. Postoperative urological complications were reviewed. Demographic details, cause of ESRD, donor type, and surgical procedures at transplant were analyzed.
Feb 28/16
http://www.urotoday.com/pediatric-urology/86707-urological-complications-following-kidney-transplantation-in-pediatric-age-a-single-center-experience.html

Portopulmonary Hypertension Seen as Important Prognosis Parameter in Liver Transplant Candidates
Researchers at the Baskent University Faculty of Medicine in Turkey recently provided an overview of the existing literature regarding portopulmonary hypertension (PoPHT) in patients with advanced liver disease and liver transplant candidates. In these patients, pulmonary hypertension is also defined as PoPHT when pulmonary arterial hypertension (PAH) is associated with portal hypertension.
The review paper, “Portopulmonary hypertension in liver transplant candidates,” was published in the World Journal of Gastroenterology.
Feb 22/16
http://pulmonaryhypertensionnews.com/2016/02/22/portopulmonary-hypertension-in-liver-transplant-candidates/

PCOS treatment: Polycystic ovary syndrome reversed through brown fat transplant
Polycystic ovary syndrome has been reversed through a brown fat transplant in rats, raising hope of a future treatment for humans with the condition. PCOS is one of the most common endocrine diseases in women of reproductive age – between 9% and 18% of women have it, yet there is no cure or treatment.
PCOS is a leading cause of infertility – it is marked by a lack of ovulation, irregular periods, cysts developing on the ovaries and high levels of androgens ("male hormones"). It is also associated with a high risk of developing insulin resistance, type-2 diabetes, obesity and cardiovascular disease.
In a study published in the journal PNAS, researchers from the Chinese Academy of Sciences note that because a single factor does not account for all the clinical features in PCOS, exactly how the condition develops is not known.
Feb 22/16
http://www.ibtimes.co.uk/pcos-treatment-polycystic-ovary-syndrome-reversed-through-brown-fat-transplant-1545299

ICBC pilot program launched to increase organ donation
Just released statistics show that 2015 was a record year in B.C. for both people donating and receiving organs, and now a new pilot program launched by ICBC will try and keep the trend going.
Starting March 1, ICBC employees at four driver licensing offices in the Lower Mainland will be encouraging customers to register a "yes" or "no" decision about becoming an organ donor in the event of an untimely death.
Currently 50 per cent of British Columbians believe they have already registered a decision on becoming an organ donor when, in fact, only 20 per cent actually have.
Feb 23/16
http://www.cbc.ca/news/canada/british-columbia/icbc-pilot-program-launched-to-increase-organ-donation-1.3458551

Donor Lungs Ready for Transplant Is Goal of Toronto Start-up Supported by $2.6M from XENiOS
Medical device company XENiOS recently announced that it has invested $2.6 million in XOR-Labs Toronto, a spin-off of Toronto General Hospital at University Health Network (UHN), a world-leading center for lung transplantation. The startup company’s organ repair technology has the potential to help thousands of patients suffering from respiratory diseases, including pulmonary fibrosis, and in urgent need of lung transplantation.
The XOR Labs Toronto system draws on technology, such as gene therapy and cell therapy, to assess and repair of donor lungs deemed unusable, and may substantially increase the amount of lungs available for transplantation. The commercial system is based on Toronto Ex Vivo Lung Perfusion (Toronto EVLP) system, which has been used over 200 times over the past six years at UHN, and it is approved by Health Canada.
Clinical data on the Toronto EVLP system, previously published in the New England Journal of Medicine, suggest that this technique can approximately double the availability of donated lungs and significantly reduce the economic costs of transplantation.
Feb 26/16
http://pulmonaryfibrosisnews.com/2016/02/26/xenios-invests-2-6-million-in-xor-labs-toronto/

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi